Physician profile
Nathan Connell
NPI 1245432467
$145,269.82
in general payments reported to CMS, 2019-2025
8 companies · $20K in 2025
The $20K reported for 2025 was more than what 83% of Hematology (Internal Medicine) providers received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $30K · 2023: $68K · 2024: $27K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $50K · Travel and Lodging: $27K · Honoraria: $21K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Food and Beverage: $2,429.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $49,747.00 |
| Travel and Lodging | $26,784.23 |
| Honoraria | $21,000.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,300.00 |
| Food and Beverage | $2,429.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $64,615.49 | 2022-2025 | Vonvendi, Advate |
| Octapharma USA, INC. | $39,093.50 | 2023-2025 | Wilate - Von Willebrand Factor/Coagulation Factor Viii Complex (Human), Nuwiq |
| Genentech USA, INC. | $20,203.12 | 2022-2025 | Hemlibra |
| Genzyme Corporation | $14,234.72 | 2023-2024 | |
| Csl Behring | $3,108.11 | 2025 | Hemgenix |
| Pfizer INC. | $2,500.00 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,136.00 | 2024 | |
| Genentech, INC. | $378.88 | 2023-2024 | Hemlibra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Connell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.